IFNA1 and type 2 diabetes mellitus: These IFN/JAK-STAT-aligned hubs complement B-cell-directed therapy (e.g., belimumab) in SLE and may delineate an immunometabolic subgroup in T2DM beyond metformin-centered metabolic control.